

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8103898

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DAVID A. RALPH	08/04/2023
JEFFREY SCOTT ARNOLD	08/09/2023
RECEIVING PARTY DATA	
Name:	NAVIDEA BIOPHARMACEUTICALS, INC.
Street Address:	4995 BRADENTON AVENUE
City:	DUBLIN
State/Country:	OHIO
Postal Code:	43017
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	18164296
PCT Number:	US2023061961
CORRESPONDENCE DATA	
Fax Number:	(612)492-7077
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6124927000
Email:	skosiek@fredlaw.com, ip@fredlaw.com
Correspondent Name:	FREDRIKSON & BYRON, P.A.
Address Line 1:	60 SOUTH 6TH STREET
Address Line 2:	SUITE 1500
Address Line 4:	MINNEAPOLIS, MINNESOTA 55402
ATTORNEY DOCKET NUMBER:	89134.19
NAME OF SUBMITTER:	TINA G. YIN SOWATZKE
SIGNATURE:	/Tina G. Yin Sowatzke/
DATE SIGNED:	08/09/2023
Total Attachments: 4	
source=89134.19.USU1_Assignments#page1.tif	
source=89134.19.USU1_Assignments#page2.tif	
source=89134.19.USU1_Assignments#page3.tif	

ASSIGNMENT

Whereas, David A. Ralph, residing at 101 East California Ave., Columbus, OH, 43202; and Jeffrey Scott Arnold, residing at 6 Pauline Drive, Andover, MA, 01810 ("Assignor"), has made invention(s) for which United States and foreign patents and patent applications have been filed or will be filed and are identified on the attached Schedule 1;

Whereas, Navidea Biopharmaceuticals, Inc., a Ohio corporation having a place of business at 4995 Bradenton Ave., Dublin, Ohio 43017 ("Assignee"), desires to acquire the entire right, title and interest in and to the United States and foreign patents and patent applications identified on the attached Schedule 1 and in and to the inventions described or claimed therein (the "Scheduled Patents"); and

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby assigns to Assignee, and its successors and assigns the following:

- (1) The entire right, title and interest to the Scheduled Patents, to each U.S. and foreign patent application and patent to which the Scheduled Patents claim priority, in whole or in part, and that claim priority, in whole or in part, to the Scheduled Patents, and to the inventions described or claimed in the Scheduled Patents (the "Patents");
- (2) The entire right, title and interest to any United States or foreign patents that may issue with respect to the inventions described or claimed in the Patents;
- (3) The entire right, title and interest to any continuations, continuations-in-part, divisions, renewals, reissues, extensions, and substitutions of the Patents; and
- (4) The right to apply for patents based on the Patents in the U.S. and foreign countries in its own name and to claim any priority rights to which such applications are entitled under international conventions, treaties or otherwise; and
- (5) The right to enforce patent rights to the Patents as fully and entirely as the same would have been held and enjoyed by the Assignors if this assignment had not been made; together with all claims by Assignors for damages by reason of past infringement or for provisional rights and including the right to sue for, and collect the same for its own use and benefit, and for the use and benefit of its successors, assigns, and other legal representatives.

Assignor further agrees for itself and for its successors and assigns to execute and deliver without further consideration any further applications, assignments or other documents and to perform such other lawful acts as Assignee, its successors and assigns may deem necessary to fully secure, maintain and enforce its rights, title or interest as outlined herein.

Assignor hereby authorizes and requests the Commissioner of Patents to issue to Assignee any patents that may be granted in accordance with this Assignment.

Assignor hereby authorizes attorneys associated with Customer No. 22859, of Fredrikson & Byron, P.A., 200 South Sixth Street, Suite 4000, Minneapolis, Minnesota, 55402-1425, to insert the application numbers, filing dates, and other identifying information on Schedule 1 when known.

This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement. The signatures from each counterpart may be combined with a copy of the Agreement to constitute the entire Agreement.


Date: Aug 4, 2023

David A. Ralph
David A. Ralph

Subscribed to and sworn to before
me this 4th day of August, 2023.

Bella Delgado-Figueroa
Notary Public

Notary Seal



Date: _____

Jeffrey Scott Arnold

Subscribed to and sworn to before
me this ____ day of _____, 2023.

Notary Public

Notary Seal

Assignor hereby authorizes and requests the Commissioner of Patents to issue to Assignee any patents that may be granted in accordance with this Assignment.

Assignor hereby authorizes attorneys associated with Customer No. 22859, of Fredrikson & Byron, P.A., 200 South Sixth Street, Suite 4000, Minneapolis, Minnesota, 55402-1425, to insert the application numbers, filing dates, and other identifying information on Schedule 1 when known.

This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement. The signatures from each counterpart may be combined with a copy of the Agreement to constitute the entire Agreement.

Date: _____

David A. Ralph

Subscribed to and sworn to before
me this ____ day of _____, 2023.

Notary Public

Notary Seal


Date: August 9, 2023

Jeffrey Scott Arnold

Subscribed to and sworn to before
me this 9 day of August, 2023.

Notary Public

Notary Seal



SCHEDULE 1

US Patent Applications

Patent App. No.	Date Filed	Title	Attorney Docket No.
63/306,719	2/4/2022	Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive Blocking	089134.0019 USP1
18/164,296	2/3/2023	ALTERING NET CHARGE ON MANNOSYLATED DEXTRANS TO MAXIMIZE TARGET TISSUE UPTAKE AND OFF TARGET COMPETITIVE BLOCKING	089134.0019.USU1

US Patents

Patent No.	Date Issued	Title

Foreign and International Patent Applications

Country	Patent App. No.	Date Filed	Title	Attorney Docket No.
WO	PCT/US23/61961	2/3/2023	ALTERING NET CHARGE ON MANNOSYLATED DEXTRANS TO MAXIMIZE TARGET TISSUE UPTAKE AND OFF TARGET COMPETITIVE BLOCKING	089134.0019.WO1

Foreign Patents

Country	Patent No.	Date of Issue	Title